+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors



Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors



World Journal of Gastroenterology 18(20): 2569-2575



To investigate the role of expressions of Ki-67, p53, epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) in gastrointestinal stromal tumor (GIST) grading and prognosis. Tumor tissue was collected retrospectively from 96 patients with GIST. Antibodies against Ki-67, p53, EGFR and COX-2 were used for immunohistochemical staining. Tumor grading was designated according to a consensus system and the staining was quantified in 3 categories for each antibody in the statistical analysis. The Ki-67 expression in GISTs was significantly associated with the size of the tumors, mitotic rate and the risk of malignancy (χ(2) = 15.51, P = 0.02; χ(2) = 22.27, P < 0.001; χ(2) = 20.05; P < 0.001). The p53 expression was also significantly correlated with mitotic rate and the risk of malignancy (χ(2) = 9.92, P = 0.04; χ(2) = 9.97; P = 0.04). Over-expression of Ki-67 was strongly correlated with poor survival (χ(2) = 10.44, P = 0.006), but no correlation was found between the expression of p53, EGFR or COX-2 and survival. Multivariate analysis further demonstrated that Ki-67 expression (relative risk = 15.78, 95% CI: 4.25-59.37) could be used as an independent prognostic value for GIST patients. Adjuvant imatinib therapy could improve clinical outcomes in the patients with high risk and intermediate risk of recurrence after complete tumor resections (median survival time: 52 mo vs 37 mo, χ(2) = 7.618, P = 0.006). Our results indicated that the expression of Ki-67 could be used as an independent prognostic factor for GIST patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 053075128

Download citation: RISBibTeXText

PMID: 22654456


Related references

Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review. Human Pathology 33(5): 478-483, 2002

Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands. Cancer Science 100(4): 654-662, 2009

Clinicopathologic features, cellular differentiation, PCNA and P53 expressions in gastrointestinal stromal tumors. Hepato-Gastroenterology 50 Suppl 2: Ccxliii-Ccxlviii, 2004

Correlation between expressions of matrix metalloproteinase-2 & 9 and vasculogenic mimicry in gastrointestinal stromal tumors. Zhonghua Yi Xue Za Zhi 89(16): 1106-1109, 2009

Relationship between gene mutations and protein expressions of PDGFR α and C-kit in gastrointestinal stromal tumors. International Journal of Clinical and Experimental Medicine 8(5): 7592-7598, 2015

Study on malignancy, staging, and grading for gastrointestinal stromal tumors. Journal of Clinical Oncology 26(15_suppl): 21521-21521, 2016

Gastrointestinal stromal tumors of the stomach: CT findings and prediction of malignancy. Ajr. American Journal of Roentgenology 183(4): 893-898, 2004

A novel correlation between LINE-1 hypomethylation and the malignancy of gastrointestinal stromal tumors. Clinical Cancer Research 16(21): 5114-5123, 2011

Prediction of risk of malignancy of gastrointestinal stromal tumors by endoscopic ultrasonography. Gut and Liver 7(6): 642-647, 2014

Comprehensive analysis of genes involved in the malignancy of gastrointestinal stromal tumors. Anticancer Research 30(7): 2705-2715, 2010

Immunohistochemistry and c-kit gene analysis in determining malignancy in gastrointestinal stromal tumors. Hepato-Gastroenterology 50(53): 1431-1435, 2003

The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annual Review of Medicine 63: 247-258, 2012

Expression of alpha6 integrin subunit is associated with malignancy in gastric gastrointestinal stromal tumors. Medical Science Monitor 13(2): Cr51-Cr56, 2007

Histopathological and clinical characteristics of duodenal gastrointestinal stromal tumors as predictors of malignancy. World Journal of Surgical Oncology 11: 202, 2015